Government Support will Aerosol Therapy Market Size

The role of aerosol therapy is expanding beyond the initial focus. This expansion eliminated CFC-based traditional metered-dose inhalers devices. This will ultimately boost the market growth of aerosol therapy in the field of gene therapy, inhalation therapy and vaccination. Aerosol therapy is a natural and easiest way to treat asthma, COPD, cystic fibrosis, and broncho pulmonary dysplasia (BPD).

Aerosol therapy is also used to deliver insulin, vaccines of influenza and measles, and pain medications. Aerosol treatment therapy gives an excellent and cost-efficient drug delivery. This therapy is effective for patients who cannot use metered-dose inhalers; primary inhalation devices are produced that guarantee breath-actuated aerosol delivery with minimal side effects.

Aerosol therapy provides a fast and non-invasive way for treatment of lung disorders as the drug is delivered at the receptor site. Effectiveness of the therapy depends on how deeply aerosol particles infiltrate into the bronchial track and where the particles are deposited. A particle size under 2μm is ideal and can permeate up to the peripheral airways. That is why most commercially available aerosol devices produce droplets of roughly this size.

As per the World Health Organization, about half the cases of asthma and COPD are due to hereditary weakness and the other cases are due to environmental factors. The effect of pollution is likely to intensify globally along with industrialization of areas, and increasing the number of vehicles.

Current government activities and rising healthcare investments are drivers of aerosol therapy market, which would upgrade over the examination time frame. Increasing prices are major factor that is restraining the growth of the market in terms of value.

Currently metered dose inhaler majorly contributes to the market and is expected to dominate the market over the forecast period. As per the data, COPD is third leading cause of death and fifth leading cause of disability. Also, factors like increasing pollution, improper lifestyles are the factors that drive the growth of the market.

On the basis of regional presence, global aerosol therapy market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. Asthma symptoms were detected in 26 million persons who live in the U.S., of which, 19 million comprise adults and 7 million comprise children. With this rate, North America is expected to dominate the market. Asia Pacific (mostly China and India) market is estimated to grow at a relatively fast rate over the forecast period.

Request for more detailed information (TOC And Sample): https://www.persistencemarketresearch.com/samples/11944

The largest manufacturers of aerosol therapy devices are Merck, Boehringer Ingelheim GmbH, GlaxoSmithKline, and AstraZeneca Plc. In 2001, SmithKline Beecham and GlaxoWellcome merged together and became GlaxoSmithKline, who became a key player in this field. Also, Novartis AGTeva Pharmaceuticals, Opko Health, Omron Healthcare Co., Covidien plc., GE Healthcare Ltd., Philips Healthcare, Agilent Technologies, Inc. Ltd, GF Health Products, Inc. are other important players in this market.

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.